The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
 
Akitaka Makiyama
No Relationships to Disclose
 
Kosuke Sagara
No Relationships to Disclose
 
Junji Kawada
No Relationships to Disclose
 
Tomomi Kashiwada
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Eisai; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Yoshiki Horie
No Relationships to Disclose
 
Hironaga Satake
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yoshiyuki Yamamoto
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Hiroaki Tanioka
No Relationships to Disclose
 
Katsunori Shinozaki
Honoraria - Asahi Kasei; Chugai Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kazuhiro Nishikawa
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical; Taiho Pharmaceutical
 
Keita Uchino
No Relationships to Disclose
 
Yasutaka Sukawa
Honoraria - Ono Pharmaceutical
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Gilead Sciences
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Shuichi Hironaka
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ichinosuke Hyodo
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Taito Esaki
Honoraria - Kyowa Hakko Kirin; Lilly
Consulting or Advisory Role - Chugai Pharma
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo; Gilead Sciences; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical; Shionogi